ReviewFrontiers in immunology2026
Anti-amphiphysin antibody positive autoimmune syndrome: case series and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Paraneoplastic neurological syndromes (PNS) is an uncommon disorder affecting the central nervous system (CNS), peripheral nervous system, or autonomic nervous system. The aim of this study was to analyze the clinical characteristics of anti-amphiphysin-IgG-positive autoimmune syndrome and to assess its association with a spectrum of anti-amphiphysin-IgG-associated autoimmune syndromes and tumors. Methods: We reported clinical data of four patients with anti-amphiphysin-IgG-positive autoimmune syndrome, and conducted a literature review. Result: Four amphiphysin-IgG-positive cases were identified. Within our cohort, antibodies feature was comprised of isolated amphiphysin-IgG (2/4), coexisting aquaporin-4-immunoglobulin G (AQP4-IgG) (1/4), coexisting N-methyl- D -aspartate receptor immunoglobulin G (NMDAR-IgG) (1/4). Clinical presentation included conus medullaris-cauda equina syndrome (1/4), myelitis (2/4) and stiff-person syndrome (SPS) (1/4). The coexisting cancer was involved of lung cancer (1/4). Conclusion: Anti-amphiphysin-IgG-positive autoimmune syndrome demonstrate heterogeneous clinical presentations, including myelitis, SPS, and rare variants like conus medullaris-cauda equina syndrome. Coexistence with other neural antibodies (e.g., AQP4-IgG or NMDAR-IgG) may elevate tumor risk. While strongly associated with malignancies such as breast and small cell lung cancer (SCLC), combined immunotherapy and oncologic therapy can stabilize or improve neurological function in subsets of patients. Early serologic testing and sustained cancer surveillance are imperative for prompt intervention and prognostic optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.